To investigate whether disengagement of embryo transfer from ovarian hyperstimulation leads to higher ongoing pregnancy rates.
ID
Bron
Verkorte titel
Aandoening
Subfertility or infertility
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Primary outcome measure will be cumulative ongoing pregnancy rate per cycle after twelve months of treatment.
Achtergrond van het onderzoek
Ovarian hyperstimulation is used in IVF/ICSI cycles to retrieve multiple oocytes. The downside of ovarian hyperstimulation is that it negatively impacts endometrial receptivity. The ENDO-RECEPT study investigates whether disengagement of embryo transfer from ovarian hyperstimulation leads to an improved ongoing pregnancy rate as compared to the standard treatment of fresh embryo transfer in a stimulated cycle.
Doel van het onderzoek
To investigate whether disengagement of embryo transfer from ovarian hyperstimulation leads to higher ongoing pregnancy rates.
Onderzoeksopzet
The duration of the study is 2.25 years.
Onderzoeksproduct en/of interventie
Ovarian hyperstimulation, oocyte retrieval and oocyte fertilization will be performed using standard procedures.
In the control arm, one or two fresh embryo(s) will be transferred in the same cycle with cryopreservation of all supernumerary embryos and subsequent transfer of frozen/thawed embryos in artificial cycles if pregnancy is not achieved after fresh transfer.
In the experimental arm, all embryos will be cryopreserved for subsequent transfer in artificial cycles.
Publiek
Femke Mol
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 556 63557
f.mol@amsterdamumc.nl
Wetenschappelijk
Femke Mol
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 556 63557
f.mol@amsterdamumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Subfertile couples with female age <43 undergoing IVF (in vitro fertilization) or ICSI (intracytoplasmatic sperm injection).
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Couples undergoing a PGD cycle;
2. Couples for which IVF/ICSI is used to prevent the transmission of HIV;
3. Couples undergoing a modified natural cycle;
5. Women with borderline or invasive ovarian cancer;
6. Women with contraindications for IVF/ICSI treatment such as cardiovascular-pulmonary disease, severe diabetes, bleeding disorders, immunodeficiency and morbid obesity;
7. Women with premature ovarian failure;
8. Women with severe psychopathology, severe anxiety and inability to cope with treatment;
9. Not able or willing to provide informed consent.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3039 |
| NTR-old | NTR3187 |
| CCMO | NL37056.000.11 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON38364 |